Background: Nasal carriage of Staphylococcus aureus is very common among health care workers, and treatment with mupirocin is one of the choicest antibiotics available. But with the rampant usage of mupirocin like other antibiotics, the emergence of mupirocin resistance is also on rise. This resistance is both low level as well as high level among the isolated strains. Aim: To screen for the high-level mupirocin resistance among the isolated Staphylococcus strains by Kirby Bauer disk diffusion method. Materials and Methods: A total of 200 clinical isolates were tested for high level mupirocin resistance by disk diffusion method using Himedia disks. Results: Among the 200 nasal swabs, 26 (13%) showed growth of S. aureus, whereas 174 (87%) showed the growth of coagulase negative staphylococcus (CONS) spp. Mupirocin resistance was observed only among CONS spp, which was 15% for low-level mupirocin and 8% for high-level mupirocin resistance. No mupirocin resistance was observed among the Staphylococcus spp. Conclusion: The identification of Mupirocin resistance will guide us to utilize the antibiotic in a judicious way to treat the nasal carriage effectively.

Keywords:
Antibiotic resistance, Low-level and high-level mupirocin resistance, Kirby Bauer disk diffusion method
1.
Moreira de Oliveira NE, Cardozo AP, Elizabeth de Andrade M. Interpretive criteria to differentiate low- and high-level mupirocin resistance in Staphylococcus aureus.
J Med Microbiol
. 2007; 56(7): 937–9.
2.
Moghadam SO, Pourmand MR. Abolfazl D A-Voodabadi, The Detection of Mupirocin Resistance and Nasal Carriage of Methicillin Resistant Staphylococcus aureus among Healthcare Workers at University Hospitals of Tehra, Iran.
Iran J Public Health
. 2015; 44(3): 361–8.
3.
Patel JB, Gorwitz RJ, Jernigan JA. Mupiro-cin Resistance.
Clin Infect Dis
. 2009; 49(6): 935–41.
4.
Lari RA, Pourmand MR, Ohadian Moghadam S, Abdossamadi Z, Ebrahimzadeh Namvar A, Asghari B. Prevalence of PVL-contain-ing MRSA isolates among hospital staff nasal carriers.
Lab Med
. 2011; 42(5): 283–6.
5.
Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F, et al. The Society of Thoracic Sur-geons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibi-otic choice.
Ann Thorac Surg
. 2007; 83: 1569–76.
6.
Udo EE, Jacob LE, Mathew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high and low-level mupirocin resistance.
J Med Microbiol
. 2001 Oct; 50(10): 909–15.
7.
Baragundi Mahesh C, Sukanya Badami V, Kulkarni Ramakant B. Kalpana Kulkarni, Mupirocin resistance in nasal isolates of Staphylococci from health care workers.
National Journal of Basic Medical Sciences
. 2015; 5(3): 1–4.
8.
Hurdle JG, O’Neill AJ, Chopra I. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide intermediate Staphylococcus aureus is not associated with a significant fitness burden.
J Antimicrob Chemother
. 2004; 53(1): 102–4.
9.
Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice.
J Antimicrob Chemother
. 1998; 41(1): 11–8.
10.
Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.
Antimicrob Agents Chemother
. 1985 Apr; 27(4): 495–8.
11.
Vivek GS, Nahalli H, Asha S, Kamath B, Nirmala A. Study of nasal carriage of MRSA among the health care workers of a tertiary care hospital, Bangalore. International Journal of Basic and Applied Medical Sciences. ISSN: 2277-2013.
12.
Agarwal L, Singh AK, Sengupta C, Agarwal A. Nasal carriage of Methicillin- and Mupirocin-resistant S. aureus among health care workers in a tertiary care hospital.
J Res Pharm Pract
. 2015 Oct-Dec; 4(4): 182–6.
13.
Dardi CK, Pandey AN. Mupirocin resistance in nasal carriage of Staphylococcus aureus among healthcare workers of a tertiary care rural hospital.
Indian J Crit Care Med
. 2014 Nov; 18(11): 716–21.
14.
Singh R, Kaore NM. Rudrakshi singh, Navinchandra M. Kaore. Screening for nasal carriage of mupirocin resistant Staphylococcus aureus among health care providers of tertiary care hospital in central India.
Indian J Microbiol Res
. 2016; 3(2): 93–8.
15.
Oommen SK, Appalaraju B, Jinsha K. Mupirocin resistance in clinical isolates of staphylococci in a tertiary care centre in south India.
Indian J Med Microbiol
. 2010; 28(4): 372–5.
16.
Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals.
J Antimicrob Chemother
. 1998; 42(4): 489–95.
17.
Jaykumar S, Meerabai M, Shameem Banu AS, Mathew R, Kalyani M, Lal YB. Prevalence of high and low level mupirocin resistance among staphylococcal isolates from skin infection in a Tertiary Care Hospital.
J Clin Diagn Res
. 2013; 7: 238–42.
18.
Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment.
Infect Control Hosp Epidemiol
. 1996; 17(12): 811–3.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.